|
|||||
|
|
Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension |
|
| Authors: | Sunil Kumar Kota Sruti Jammula Siva Krishna Kota Lalit Kumar Meher Kirtikumar D. Modi |
| Affiliation: | 1. Department of Endocrinology, Medwin Hospital, Room- 258, Raghava Ratna Towers, Chirag Ali Lane, Nampally, Hyderabad, 500001, Andhra Pradesh, India 2. Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Khodasingi, Ambapua, Berhampur, 760010, Orissa, India 3. Department of Anaesthesia, Central Security Hospital, C/O- AMISAL, Xenel building, Dabab street, Near Tamimi Market, PO Box- 3886, Riyadh, 11481, Saudi Arabia 4. Department of Medicine, MKCG Medical College, Berhampur, 760004, Orissa, India |
| Abstract: | Resistant hypertension is common in diabetes. Spironolactone by inhibiting aldosterone not only exerts antihypertensive effect but also antiproteinuric effect. In this study, the mean decrease in systolic and diastolic blood pressure after 4?weeks of spironolactone was 25.5?±?7.8 and 11.4?±?3.5?mmHg respectively and it increased further at 8?weeks and at 12?weeks, while there was no significant change in blood pressure in the control group. At 12?weeks, significantly greater reductions in both the systolic and diastolic blood pressure were observed in patients treated with spironolactone having serum potassium less than 4?meq/l vs those having serum potassium more than 4?meq/l. Reduction in urine microalbumin, though higher in patients with serum potassium less than 4?meq/l was not significant at any intervals. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |